GLPwatch
[The glucagon-like peptide-1 receptor-agonist semaglutide].
Ugeskr Laeger · 2019
Last updated 2026-05-28Semaglutide is a once-weekly injectable drug for Type 2 diabetes. In studies involving over 8,000 patients, it improved blood sugar control and led to weight loss more effectively than other diabetes medications. It also reduced the risk of cardiovascular events compared to standard treatments.
AI summary of the abstract below.
| Journal | Ugeskr Laeger, 2019 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.04 |
| NIH percentile | 4 |
| Molecules | semaglutide |
| Conditions studied | Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction |
Abstract
Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basalinsulin. In addition, semaglutide significantly decreased the occurrence of cardiovascular events compared with standard pharmacological diabetic treatment combined with placebo.
Verbatim abstract via PubMed 31610830 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.